Is McKesson Corporation (MCK) overvalued or fairly valued?

MarketChacha shows McKesson Corporation's valuation in context — a trailing P/E of about 28.8, a forward P/E of about 17.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does McKesson Corporation's reported profit turn into cash?

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.49×) from reported figures — education, not a rating.

What is McKesson Corporation's revenue?

McKesson Corporation reported revenue of $403.4B for FY2026, with net profit of $4.8B, per official filings.

What is the share price of McKesson Corporation (MCK)?

McKesson Corporation last traded at $859.92 (-1.0% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

McKesson Corporation

MCK · NYSE · Healthcare · United States

Snapshot

TickerMCK

ExchangeNYSE

SectorHealthcare

IndustryMedical Distribution

CountryUnited States

Employees41,600

HeadquartersIrving, United States

Websitewww.mckesson.com

Filings tracked20

About McKesson Corporation

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

Who owns it

Insiders0.1%
Institutions94.4%
Public & other5.5%

2,655 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.26%
Vanguard Capital Management LLC6.74%
State Street Corporation4.91%
Morgan Stanley4.55%
Franklin Resources, Inc.2.49%
Vanguard Portfolio Management LLC2.46%
Geode Capital Management, LLC2.42%
Massachusetts Financial Services Co.2.10%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.49×

Over 4 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend1.3% → 1.2%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 13% · PAT 10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $113.1B · EPS 11.00

Est. earnings growth +17.8%

Next fiscal year

Rev $462.5B · EPS 50.53

Est. earnings growth +13.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2026)

$403.4B

Net margin

1.2%

Revenue CAGR (3y)

+13.4%

Profit CAGR (3y)

+10.2%

EPS (FY2026)

38.38

Net profit (FY2026)

$4.8B

Ask MarketChacha about MCK

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	$403.4B	$4.8B	38.38	1.2%
FY2025	$359.1B	$3.3B	25.72	0.9%
FY2024	$309.0B	$3.0B	22.39	1.0%
FY2023	$276.7B	$3.6B	25.03	1.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$105.4B	$614.0M	5.15	0.6%
2025Q4	$106.2B	$1.2B	9.59	1.1%
2025Q3	$103.2B	$1.1B	8.92	1.1%
2025Q2	$97.8B	$784.0M	6.25	0.8%
2024Q4	$95.3B	$879.0M	6.95	0.9%
2024Q3	$93.7B	$241.0M	1.87	0.3%
2024Q2	$79.3B	$915.0M	7.00	1.2%
2023Q4	$80.9B	$589.0M	4.42	0.7%
2023Q3	$77.2B	$664.0M	4.92	0.9%
2023Q2	$74.5B	$958.0M	7.02	1.3%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/5/2026material
10-Q filing
SEC8/5/2026
8-K — Shareholder vote results
SEC7/24/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC7/1/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/12/2026material
10-K filing
SEC5/8/2026
8-K — Results of operations, Exhibits
SEC5/7/2026material
8-K — Material agreement, Termination of agreement, Material financial obligation, Exhibits
SEC4/28/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC4/6/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/6/2026material
8-K — Executive/director change, Exhibits
SEC3/5/2026material
8-K — Results of operations, Exhibits
SEC2/4/2026material
10-Q filing
SEC2/4/2026

2025

10-Q filing
SEC11/6/2025
8-K — Results of operations, Exhibits
SEC11/5/2025material
8-K — Reg FD disclosure, Exhibits
SEC9/23/2025material
8-K — Results of operations, Other events, Exhibits
SEC9/18/2025material
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025
8-K — Shareholder vote results
SEC8/1/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.